Lucid Diagnostics Inc. LUCD
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease ("GERD"), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma ("EAC").
We believe that our flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread testing tool with the goal of preventing EAC deaths, through early detection of esophageal precancer in at-risk GERD patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377.0K | $500.0K | — | — |
| Cost of revenue | $6.7M | $7.1M | — | $100.0M | $585.0K | — | — |
| Gross profit | -$2.0M | -$2.8M | — | $377.0K | $500.0K | — | — |
| R&D | $5.7M | $6.0M | $7.3M | $11.3M | $9.3M | $5.4M | — |
| SG&A | $23.9M | $20.2M | $19.3M | $24.0M | $21.0K | $7.0K | — |
| Total operating expenses | $54.3M | $50.4M | $50.9M | $56.6M | $27.9M | $8.3M | — |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M | -$27.4M | -$8.3M | — |
| Interest expense | $22.0K | $26.0K | $416.0K | $8.0K | — | — | — |
| Pre-tax income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M | -$8.3M | — |
| Income tax | $0 | $0 | — | — | — | — | — |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M | -$28.1M | -$8.3M | — |
| EPS, basic | -0.69 | -1.05 | -1.26 | -1.55 | -1.51 | — | — |
| EPS, diluted | — | -1.05 | -1.26 | -1.55 | -1.51 | -0.59 | — |
| Shares, diluted (wtd. avg.) | 101.9M | 50.5M | 41.8M | 36.2M | 18.6M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | $22.4M | $18.9M | $22.5M | $53.7M | — | — |
| Receivables | $643.0K | $45.0K | $45.0K | $17.0K | $200.0K | — | — |
| Inventory | $353.0K | $341.0K | $278.0K | $111.0K | — | — | — |
| Total current assets | $37.5M | $25.1M | $22.1M | $24.4M | $57.3M | $1.4M | — |
| Property, plant and equipment | $809.0K | $1.1M | $1.3M | $1.6M | $971.0K | — | — |
| Other intangibles | $315.0K | $736.0K | $1.4M | $3.4M | — | — | — |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M | $2.2M | — |
| Accounts payable | $970.0K | $1.2M | $1.1M | $1.1M | $1.5M | $2.1M | — |
| Total current liabilities | $28.6M | $23.5M | $29.4M | $8.4M | $4.3M | — | — |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M | $15.7M | — |
| Retained earnings | -$274.3M | -$203.8M | -$150.7M | -$98.1M | -$41.9M | -$13.8M | — |
| Total equity | $10.9M | $5.4M | -$2.3M | $23.0M | $54.7M | -$13.5M | -$5.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.5M | -$44.1M | -$32.8M | -$29.7M | -$17.7M | -$5.6M | — |
| Depreciation and amortisation | $872.0K | $1.2M | $2.5M | $1.9M | $4.0K | — | — |
| Stock-based compensation | — | $4.2M | $5.8M | $13.9M | $9.1M | $65.0K | — |
| Capital expenditure | $197.0K | $296.0K | — | $3.2M | $862.0K | — | — |
| Investing cash flow | -$197.0K | -$646.0K | -$221.0K | -$4.1M | -$862.0K | — | — |
| Financing cash flow | $59.0M | $48.2M | $29.5M | $2.6M | $72.1M | $5.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-009805.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $500.0K | $377.0K | $2.4M | $4.3M | $4.7M |
| Gross profit | — | — | $500.0K | $377.0K | — | -$2.8M | -$2.0M |
| Net income | — | -$8.3M | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |